Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome

Journal of Clinical Oncology

Volumn 25, Issue 19, 2007, Pages 2650-2655

  Mazouni, Chafika ^a   Peintinger, Florentia ^a   Wan Kau, Shu ^a   Andre, Fabrice ^a   Gonzalez Angulo, Ana M ^a   Symmans, W Fraser ^a   Meric Bernstam, Funda ^a   Valero, Vicente ^a   Hortobagyi, Gabriel N ^a   Pusztai, Lajos ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; PACLITAXEL; PREDNISONE; TAXANE DERIVATIVE; VINCRISTINE;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMA IN SITU; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME; ADJUVANT THERAPY; ADOLESCENT; AGED; BREAST TUMOR; DISEASE FREE SURVIVAL; LYMPH NODE METASTASIS; METHODOLOGY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; PAGET NIPPLE DISEASE; PATHOLOGY; RECURRENT DISEASE; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM, RESIDUAL; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34447577933     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.2271     Document Type: Article

References (29)

1. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
2. Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic neoadjuvant tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999
3. Carey LA, Metzger R, Dees EC, et al: American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst 97:1137-1142, 2005
4. Mauriac L, MacGrogan G, Avril A, et al: Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124-month median follow-up - Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10:47-52, 1999
5. Guarneri V, Broglio K, Kau SW, et al: Prognostic value of pathologic complete response after neoadjuvant chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037-1044, 2006
6. Amat S, Abrial C, Penault-Llorca F, et al: High prognostic significance of residual disease after neoadjuvant chemotherapy: A retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 94:255-263, 2005
7. Bear HD, Anderson S, Brown A, et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174, 2003
8. Green MC, Buzdar AU, Smith T, et al: Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23:5983-5992, 2005
9. Ayers M, Symmans WF, Stec J, et al: Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22:2284-2293, 2004
10. Gianni L, Zambetti M, Clark K, et al: Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23:7265-7277, 2005
11. Rouzier R, Extra JM, Klijanienko J, et al: Incidence and prognostic significance of complete axillary down-staging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 20:1304-1310, 2002
12. Ogston KN, Miller ID, Payne S, et al: A new histological grading system to assess response of breast cancers to primary chemotherapy: Prognostic significance and survival. Breast 12:320-327, 2003
13. Sataloff DM, Mason BA, Prestipino AJ, et al: Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome. J Am Coll Surg 180:297-306, 1995
14. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al: Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update. J Clin Oncol 24:1940-1949, 2006
15. Estevez LG, Gradishar WJ: Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res 10:3249-3261, 2004
16. Valero V, Buzdar AU, McNeese M, et al: Primary chemotherapy in the treatment of breast cancer: The University of Texas M.D. Anderson Cancer Center experience. Clin Breast Cancer 3:S63-S68, 2002 (suppl 2)
17. Black MM, Speer FD: Nuclear structure in cancer tissues. Surg Gynecol Obstet 105:97-102, 1957
18. Jones RL, Lakhani SR, Ring AE, et al: Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma. Br J Cancer 94:358-362, 2006
19. Chollet P, Amat S, Cure H, et al: Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 86:1041-1046, 2002
20. Hennessy BT, Hortobagyi GN, Rouzier R, et al: Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23:9304-9311, 2005
21. Ernster VL, Barclay J, Kerlikowske K, et al: Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 275:913-918, 1996
22. Hetelekidis S, Schnitt SJ, Morrow M, et al: Management of ductal carcinoma in situ. CA Cancer J Clin 45:244-253, 1995
23. Fisher B, Dignam J, Wolmark N, et al: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353:1993-2000, 1999
24. Kerlikowske K, Molinaro A, Cha I, et al: Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 95:1692-1702, 2003
25. National Comprehensive Cancer Network: Practice Guidelines in Oncology: Breast Cancer, Version 2, 2007. http://www.nccn.org/professionals/physician_gls/ PDF/breast.pdf
26. Rudas M, Neumayer R, Gnant MF, et al: p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur J Cancer 33:39-44, 1997
27. Cardillo MR, Stamp GW, Pignatelli M: Proliferating cell nuclear antigen in benign breast disease. Eur J Gynaecol Oncol 16:476-481, 1995
28. Pusztai L, Siddik ZH, Mills GB, et al: Physiologic and pathologic drug resistance in ovarian carcinoma: A hypothesis based on a clonal progression model. Acta Oncol 37:629-640, 1998
29. Cody HS, Klauber-DeMore N, Borgen PI, et al: Is it really duct carcinoma in situ? Ann Surg Oncol 8:617-619, 2001